


## Phenacetin

Cat. No.:	HY-B0476		
CAS No.:	62-44-2		
Molecular Formula:	C <sub>10</sub> H <sub>13</sub> NO <sub>2</sub>		
Molecular Weight:	179.22		
Target:	COX		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (557.97 mM)  
 H<sub>2</sub>O : 0.67 mg/mL (3.74 mM; Need ultrasonic)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	5.5797 mL	27.8987 mL	55.7973 mL
	5 mM	1.1159 mL	5.5797 mL	11.1595 mL
	10 mM	0.5580 mL	2.7899 mL	5.5797 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (13.95 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (13.95 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (13.95 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Phenacetin (Acetophenetidin) is a non-opioid analgesic/antipyretic agent. Phenacetin is a selective COX-3 inhibitor. Phenacetin is used as probe of cytochrome P450 enzymes CYP1A2 in human liver microsomes and in rats<sup>[1][2][3]</sup>.

#### IC<sub>50</sub> & Target

COX-3  
102 μM (IC<sub>50</sub>)

<b>In Vitro</b>	<p>Phenacetin shows inhibitory activity for COX-3 with an IC<sub>50</sub> value of 102 μM in insect cells [1].  Phenacetin is a substrate widely used as an in vitro and in vivo probe to measure the activity of CYP1A2, because the metabolism of phenacetin to acetaminophen is thought to be a selective CYP1A2-mediated reaction[2][3].  MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
<b>In Vivo</b>	<p>Phenacetin exhibits elimination half-life (rat 2.06 h) and C<sub>max</sub> (6,728.3 μg/L) following oral administration (rat 20 mg/kg)[2].  MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="342 380 1513 617"> <tr> <td data-bbox="342 380 613 443">Animal Model:</td> <td data-bbox="613 380 1513 443">Male Sprague-Dawley rats (180-200 g)[2]</td> </tr> <tr> <td data-bbox="342 443 613 506">Dosage:</td> <td data-bbox="613 443 1513 506">20 mg/kg</td> </tr> <tr> <td data-bbox="342 506 613 569">Administration:</td> <td data-bbox="613 506 1513 569">Oral administration (Pharmacokinetic Analysis)</td> </tr> <tr> <td data-bbox="342 569 613 617">Result:</td> <td data-bbox="613 569 1513 617">T<sub>1/2</sub> (2.06 hours), C<sub>max</sub> (6,728.3 μg/L).</td> </tr> </table>	Animal Model:	Male Sprague-Dawley rats (180-200 g)[2]	Dosage:	20 mg/kg	Administration:	Oral administration (Pharmacokinetic Analysis)	Result:	T <sub>1/2</sub> (2.06 hours), C <sub>max</sub> (6,728.3 μg/L).
Animal Model:	Male Sprague-Dawley rats (180-200 g)[2]								
Dosage:	20 mg/kg								
Administration:	Oral administration (Pharmacokinetic Analysis)								
Result:	T <sub>1/2</sub> (2.06 hours), C <sub>max</sub> (6,728.3 μg/L).								

## REFERENCES

- [1]. Chandrasekharan NV, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31.
- [2]. Xiao-Meng He, et al. Effects of long-term smoking on the activity and mRNA expression of CYP isozymes in rats. J Thorac Dis. 2015 Oct; 7(10): 1725-1731.
- [3]. Na Gao, et al. Inhibition of Baicalin on Metabolism of Phenacetin, a Probe of CYP1A2, in Human Liver Microsomes and in Rats. PLoS One. 2014; 9(2): e89752.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA